STOCK TITAN

Vireo Growth Inc reported $268.8M in revenue and a $68.1M net loss for fiscal 2025. See the full VREOD financial statements: income statement, balance sheet, cash flow and ratios, each column linked to its SEC filing.

Vireo Growth Announces Conference Attendance for September 2026

Vireo Growth will meet investors at a New York life sciences conference, supported by an updated Q2 2026 investor presentation online.

(Moderate)
(Neutral)
Tags

Vireo Growth (VREOD, VREOF) plans to attend the ATB Cormark Capital Markets 2026 Life Sciences Fall Institutional Investor Conference on September 9, 2026, in New York City.

Chief Financial Officer Tyson Macdonald will hold one-on-one meetings with investors. The company’s current Q2 2026 investor presentation is available on its investor relations website.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

Market Context

The July 2 Pennsylvania license transaction generated a 4.08% 24-hour move, while the June 18 acquis...
Analysis

The July 2 Pennsylvania license transaction generated a 4.08% 24-hour move, while the June 18 acquisition recorded -6.13%. This conference notice added no operating result; future disclosures remain the key item to watch.

Key Figures

Announcement date: September 2, 2026 Conference date: September 9, 2026 Investor presentation period: Q2 2026
3 metrics
Announcement date September 2, 2026 Conference attendance announcement
Conference date September 9, 2026 ATB Cormark Capital Markets 2026 Life Sciences Fall Institutional Investor Conference
Investor presentation period Q2 2026 Current investor presentation

Historical Context

2 past events · Latest: Jul 02 (Positive)
Pattern 2 events
Date Event Sentiment 24h Move Catalyst
Jul 02 license transaction Positive +4.1% Expansion into Pennsylvania’s 11th state involved a permit supporting up to six dispensaries.
Jun 18 dispensary acquisition Positive -6.1% Completed purchase of a 49% Maryland dispensary interest for $1.55 million.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Historical acquisition announcements showed mixed reactions: one aligned with a gain, while another diverged on a decline.

Key Terms

otcqx
1 terms
otcqx financial
"Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF)"
OTCQX is the highest tier of the over‑the‑counter (OTC) marketplaces where shares of companies that aren’t listed on major stock exchanges trade. Think of it as a “premium shelf” for OTC stocks: companies must meet stricter financial and disclosure standards, which can mean clearer information, potentially better investor confidence and somewhat easier trading than lower OTC tiers. Investors watch OTCQX listings as a signal of relative transparency and credibility among OTC-traded firms.
View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

MINNEAPOLIS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo” or the “Company”), a leading vertically integrated cannabis company and agricultural markets platform, today announced that it will attend the following conference:

ATB Cormark Capital Markets 2026 Life Sciences Fall Institutional Investor Conference
Chief Financial Officer, Tyson Macdonald, will participate in investor one-on-one meetings.
DATE: September 9, 2026
LOCATION: New York City, NY

Vireo’s current Q2 2026 investor presentation is available on the Company’s investor relations website at: https://investors.vireogrowth.com/events-and-presentations

About Vireo Growth Inc.

Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) is a leading vertically integrated cannabis company building a broad platform across cannabis and adjacent agricultural markets. The Company operates cultivation, manufacturing, retail dispensaries, home delivery, distribution, and agricultural supply businesses across the United States, creating exposure to both cannabis and complementary adjacent markets. With operations in 10 states and more than 170 dispensaries nationwide, Vireo combines disciplined capital allocation, strategic acquisitions, and local market execution to scale its platform and drive long-term shareholder value. The Company is focused on expanding market share and strengthening its portfolio of consumer brands and services, while supporting the customers, employees, shareholders, and communities it serves. For more information about Vireo, visit www.vireogrowth.com.

Contact Information:

Lynn Ricci
Director Investor Relations & Corporate Communications
investor@vireogrowth.com 
(781) 956-7052


FAQ

When will Vireo Growth (VREOD) attend the ATB Cormark life sciences conference?

Vireo Growth is scheduled to attend the ATB Cormark Capital Markets 2026 Life Sciences Fall Institutional Investor Conference on September 9, 2026, in New York City, NY. The company’s Chief Financial Officer will participate in one-on-one investor meetings.

Who will represent Vireo Growth (VREOD) at the September 2026 investor conference?

Vireo Growth will be represented by its Chief Financial Officer, Tyson Macdonald, who will participate in one-on-one meetings with investors during the ATB Cormark Capital Markets 2026 Life Sciences Fall Institutional Investor Conference.

Where can investors find Vireo Growth’s Q2 2026 presentation mentioned in the conference announcement?

Investors can access Vireo Growth’s current Q2 2026 investor presentation on the company’s investor relations website at https://investors.vireogrowth.com/events-and-presentations, which is highlighted in connection with the September 2026 conference attendance.

What type of investor meetings will Vireo Growth (VREOF) hold at the September 2026 conference?

At the ATB Cormark Capital Markets 2026 Life Sciences Fall Institutional Investor Conference, Vireo Growth’s Chief Financial Officer, Tyson Macdonald, will participate in one-on-one meetings with investors, offering direct engagement opportunities with the company’s management.